[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334069-105":59,"doc-detail-334069-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tp53-mutations-in-cancer-molecular-features-and-therapeutic-opportunities-review","TP53 mutations in cancer - Molecular features and therapeutic opportunities - Review","","The tumour suppressor p53 orchestrates key cellular programs including cell-cycle regulation, DNA repair, apoptosis, autophagy, metabolism and immune responses. TP53 is the most frequently mutated gene in human cancers, where non-synonymous variants often yield mutant p53 proteins with loss-of-function, dominant-negative effects on p53 tetramerisation, and gain-of-function oncogenic activities. Evidence from cancer-derived models indicates that restoring wild-type p53 activity, rather than only blocking gain-of-function, can reduce tumour growth. Accordingly, therapeutic strategies may include small molecules, gene therapy and other approaches aimed at re-establishing wild-type p53 function.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tp53-mutations-in-cancer-molecular-features-and-therapeutic-opportunities-review/334069/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tp53-mutations-in-cancer-molecular-features-and-therapeutic-opportunities-review/334069.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What roles does p53 play in normal cells?","Question",{"text":112,"@type":113},"p53 regulates cell-cycle control, DNA repair, apoptosis, autophagy, cell metabolism and immune response, helping coordinate responses to cellular stress and damage.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do TP53 mutations typically affect p53 function in cancers?",{"text":117,"@type":113},"Most TP53 mutations are non-synonymous and produce mutant p53 proteins that show loss of function, a dominant-negative effect on p53 tetramerisation, and gain-of-function oncogenic properties.",{"name":119,"@type":110,"acceptedAnswer":120},"Why might reactivating wild-type p53 be a better strategy than only halting mutant gain-of-function?",{"text":121,"@type":113},"Studies cited in the review report that restoring wild-type p53, rather than removing gain-of-function mutations, reduces cancer cell growth, suggesting greater therapeutic benefit.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334069,1790465088,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 55: 7, 2025  \nTP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)  \nMARIA LINA TORNESELLO  \nMolecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, I-80131 Napoli, Italy  \nReceived July 10, 2024; Accepted September 3, 2024  \nDOI: 10.3892/ijmm.2024.5448  \nAbstract. The tumour suppressor factor p53 plays an essential role in regulating numerous cellular processes, including the cell cycle, DNA repair, apoptosis, autophagy, cell metabolism and immune response. TP53 is the most commonly mutated gene in human cancers . These mutations are primarily non‑synonymous changes that produce mutant p53 proteins characterized by loss of function, a dominant negative effect on p53 tetramerisation and gain of function (GOF) . GOF mutations not only disrupt the tumour‑suppressive activities of p53 but also endow the mutant proteins with new oncogenic properties . Recent studies analysing different pathogenic features of mutant p53 in cancer‑derived cell lines have demon‑ strated that restoring wild‑type p53, rather than removing GOF mutations, reduces cancer cell growth. These findings suggest that therapeutic strategies for reactivating wild‑type p53 function in cancer cells may bring a greater benefit than approaches halting mutant p53 . This approach could involve the use of small molecules, gene therapy and other methods tore‑establish wild‑type p53 activity. This review describes the complexity of the biological activities of different p53 mutants and summarizes the current therapeutic approaches to restore p53 function.  \nContents  \n1. Introduction  \n2. Mutations in TP53 gene  \n3. Therapeutic strategies to target mutant p53  \n4. Conclusions  \nCorrespondence to: Dr Maria Lina Tornesello, Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Via Mariano Semmola 52, I-80131 Napoli, Italy  \nE‑[mail: m.tornesello@istitutotumori.na.it](mail: m.tornesello@istitutotumori.na.it)  \nKey words: dominant negative effect, gain‑of‑function, loss‑of‑function, missense mutations, therapy, TP53, tumour suppressor  \n1. Introduction  \nThe p53 protein was first described in 1979 by several research groups as a cellular factor forming a complex with the simian virus 40 large tumour antigen (1,2) . Subsequent studies demonstrated excessive accumulation of p53 both in cells expressing viral tumour antigens and in cancer cells negative for viral infections, whereas p53 levels were low in normal, uninfected cells (3,4) . In the early 1980s, p53 was recognised as an oncoprotein whose upregulation by tumour viruses or other mechanisms could contribute to cellular transforma‑ tion (5,6) . Indeed, the TP53 cDNA cloned from various cancer cell lines was shown to immortalise primary cells, induce multilayer cell growth and promote tumourigenicity in animal models, thereby experimentally substantiating the oncogenic role of p53 in tumour development (7,8) . In the late 1980s, DNA sequencing of the TP53 gene isolated from tumour cells revealed frequent missense mutations conferring oncogenic features to the mutant p53 proteins (9,10) . Conversely, the expression of wild‑type p53 in transformed cells was shown to suppress the transformed phenotype without inducing damaging effects in non‑transformed cells (11,12) . The critical role of p53 as a tumour suppressor was further demonstrated in patients with Li‑Fraumeni syndrome, associated with monoallelic germline TP53 mutations and characterized by a high predisposition to various cancer types, including breast cancer, sarcomas, brain tumours, leukaemia and adrenal gland cancers (13,14) . The observation that tumours developing inpatients with Li‑Fraumeni syndrome have lost the wild‑type TP53 allele definitively established p53 as a tumour suppressor factor (15) .  \nThe scientific evidence accumulated over the past 40 years since the discovery of p53 has shown that","cbCaisp0F09WrmLi","https://ap.wps.com/l/cbCaisp0F09WrmLi","pdf",1921300,11,"English","# Contents\n## 1. Introduction\n## 2. Mutations in TP53 gene\n## 3. Therapeutic strategies to target mutant p53\n## 4. Conclusions","[{\"question\":\"What roles does p53 play in normal cells?\",\"answer\":\"p53 regulates cell-cycle control, DNA repair, apoptosis, autophagy, cell metabolism and immune response, helping coordinate responses to cellular stress and damage.\"},{\"question\":\"How do TP53 mutations typically affect p53 function in cancers?\",\"answer\":\"Most TP53 mutations are non-synonymous and produce mutant p53 proteins that show loss of function, a dominant-negative effect on p53 tetramerisation, and gain-of-function oncogenic properties.\"},{\"question\":\"Why might reactivating wild-type p53 be a better strategy than only halting mutant gain-of-function?\",\"answer\":\"Studies cited in the review report that restoring wild-type p53, rather than removing gain-of-function mutations, reduces cancer cell growth, suggesting greater therapeutic benefit.\"}]","TP53 mutations in cancer - Molecular features and therapeutic opportunities - Review | PDF",1790005186,28]